Hostname: page-component-78c5997874-j824f Total loading time: 0 Render date: 2024-11-19T06:07:41.876Z Has data issue: false hasContentIssue false
  • English
  • Français

Plasma Prolactin and Growth Hormone Levels in Manic Patients Treated with Pimozide

Published online by Cambridge University Press:  29 January 2018

J. C. Cookson ,
T. Silverstone  and
Lesley Rees
J. C. Cookson
Affiliation:
Department of Psychological Medicine
T. Silverstone
Affiliation:
Department of Psychological Medicine
Lesley Rees
Affiliation:
Medical College of St Bartholomew's Hospital, London EC1
Get access Rights & Permissions [Opens in a new window]

Summary

During two weeks' treatment of 11 manic patients with pimozide there was close correspondence between the timecourse of improvement in clinical ratings and the rise in plasma prolactin between the second and fourteenth day. There were no significant differences in growth hormone levels during the manic episodes compared to recovery. These findings are discussed in relation to the role of dopamine in the release of prolactin and growth hormone, and in the pathogenesis of mania.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 140 , Issue 3 , March 1982 , pp. 274 - 279
Copyright
Copyright © Royal College of Psychiatrists, 1982 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Besser, G. M., Butler, P. W. P., Landon, J. & Rees, L. (1969) Influence of amphetamines on plasma corticosteroid and growth hormone levels in man. British Medical Journal, iv, 528–30.Google Scholar
Besser, G. M., Delitala, G., Grossman, A., Stubbs, W. A. & Yeo, T. (1980) Chlorpromazine, haloperidol, metoclopramide and domperidone release prolactin through dopamine antagonism at low concentrations but paradoxically inhibit prolactin release at high concentrations. British Journal of Pharmacology, 71, 569–73.CrossRefGoogle ScholarPubMed
Brown, W. A. (1977) Psychologic and neuroendocrine response to methylphenidate. Archives of General Psychiatry, 34, 1103–8.CrossRefGoogle ScholarPubMed
Checkley, S. A. (1980) Neuroendocrine tests of monoamine function in man: A review of basic theory and the application to the study of depressive illness. Psychological Medicine, 10, 35–53.CrossRefGoogle Scholar
Cookson, J. C., Silverstone, T. & Wells, B. (1982) A double-blind comparative trial of pimozide and chlorpromazine in mania: A test of the dopamine hypothesis. Acta Psychiatrica Scandinavica, (in press).CrossRefGoogle Scholar
Cotes, P. M., Crow, T. J., Johnstone, E. C., Bartlett, W. & Bourne, R. C. (1978) Neuroendocrine changes in acute schizophrenia as a function of clinical state and neuroleptic medication. Psychological Medicine, 8, 657–65.Google Scholar
Crow, T. J., Frith, C. D., Johnstone, E. C. & Owens, D. G. C. (1981) The timecourse of the anti-psychotic effect in schizophrenia. British Journal of Psychiatry, 139, 250.Google Scholar
Davis, G. C., Extein, I., Reus, V. I., Hamilton, W., Post, R. M., Goodwin, F. K. & Bunney, W. E. (1980) Failure of naloxone to reduce manic symptoms. American Journal of Psychiatry, 137, 1583–5.Google Scholar
Feighner, J. P., Robins, E., Guze, S. B., Woodruff, R. A., Winokur, G. & Munoz, R. (1972) Diagnostic criteria for use in psychiatric research. Archives of General Psychiatry, 26, 517–63.Google Scholar
Gruen, P. H., Sachar, E. J., Langer, G., Altmann, N., Leifer, M., Frantz, A. & Halpern, F. S. (1978) Prolactin responses to neuroleptics in normal and schizophrenic subjects. Archives of General Psychiatry, 35, 108–16.Google Scholar
Gudelsky, G. A. (1981) Tubero-infundibular dopamine neurones and the regulation of prolactin secretion. Psychoneuroendocrinology, 6, 3–16.Google Scholar
Huey, L. Y., Janowsky, D. S., Judd, L. L., Roitman, N. A., Clopton, P. L., Segal, D., Hall, L. & Parker, D. (1980) The effects of naloxone on methylphenidate-induced mood and behavioural changes: A negative study. Psychopharmacology, 67, 125–30.CrossRefGoogle ScholarPubMed
Janowsky, D. S., El-Yousef, M. & Davis, J. (1973a) Provocation of schizophrenic symptoms by intravenous administration of methylphenidate. Archives of General Psychiatry, 28, 185–91.CrossRefGoogle ScholarPubMed
Janowsky, D. S., El-Yousef, M. K. & Sekerke, H. J. (1973b) Antagonistic effects of physostigmine and methylphenidate in man. American Journal of Psychiatry, 130, 1370–6.CrossRefGoogle ScholarPubMed
Janowsky, D. S., Judd, L., Huey, L., Roitman, N. & Parker, D. (1979) Naloxone effects on serum growth hormone and prolactin in man. Psychopharmacology, 65, 95–7.Google Scholar
Jonsson, L. E. (1972) Pharmacological blockade of amphetamine effects in amphetamine dependent subjects. European Journal of Clinical Pharmacology, 4, 206–11.Google Scholar
Kolakowska, T., Orr, M., Gelder, M., Heggie, M., Wiles, D. & Franklin, M. (1979) Clinical significance of plasma drug and prolactin levels during acute chlorpromazine treatment: A replication study. British Journal of Psychiatry, 135, 352–9.Google Scholar
Kolakowska, T., Fraser, S., Franklin, M. & Knox, J. (1981) Neuroendocrine tests during treatment with neuroleptic drugs. Psychopharmacology, 72, 283–5.Google Scholar
Lal, S., De La Vega, C. E., Sourkes, T. L. & Friesen, H. (1973) Effect of apomorphine on growth hormone, prolactin, luteinizing hormone, follicle stimulating hormone in human serum. Journal of Clinical Endocrinology and Metabolism, 37, 719–24.Google Scholar
McCreadie, R. G., Heykants, J. J. P., Chalmers, A. & Anderson, A. M. (1979) Plasma pimozide profiles in chronic schizophrenics. British Journal of Clinical Pharmacology, 7, 533–4.Google Scholar
Meltzer, H. Y. & Fang, V. S. (1976) The effect of neuroleptics on serum prolactin in schizophrenic patients. Archives of General Psychiatry, 33, 279–86.Google Scholar
Michiels, L. J. M., Heykants, J. J. P., Knaeps, A. G. & Janssen, P. A. J. (1975) Radioimmunoassay for the neuroleptic drug pimozide. Life Sciences, 16, 937–44.Google Scholar
Mielke, D. H., Gallant, D. M. & Kessler, C. (1977) An evaluation of a unique anti-psychotic agent, sulpiride: Effects on serum prolactin and growth hormone. American Journal of Psychiatry, 134, 1370–5.Google Scholar
Ohman, R. & Axelsson, R. (1978) Relationship between prolactin response and antipsychotic effect of thioridazine in psychiatric patients. European Journal of Clinical Pharmacology, 14, 111–16.CrossRefGoogle ScholarPubMed
Ohman, R., Forsman, A. & Larsson, M. (1980) Prolactin response to haloperidol after a single dose and during prolonged administration. Current Therapeutic Research, 27, 137–42.Google Scholar
Petterson, U., Fyro, B. & Sedvall, G. (1973) A new scale for the longitudinal rating of manic states. Acta Psychiatrica Scandinavica, 49, 248–56.Google Scholar
Pinder, R. M., Brogden, R. N., Sawyer, P. R., Speight, T. M., Spencer, R. & Avery, G. S. (1976) Pimozide: A review of its pharmacological properties and therapeutic uses in psychiatry. Drugs, 12, 1–40.Google Scholar
Post, R. M., Jimerson, D. C., Bunney, W. E. Jr. & Goodwin, F. K. (1980) Dopamine and mania: Behavioural and biochemical effects of the dopamine receptor blocker pimozide. Psychopharmacology, 67, 297–305.Google Scholar
Rees, L., Butler, P. W. P., Gosling, C. & Besser, G. M. (1970) Adrenergic blockade and the corticosteroid and growth hormone response to methylamphetamine. Nature, 228, 565–6.CrossRefGoogle ScholarPubMed
Rubin, R. T. & Hays, S. E. (1980) The prolactin secretory response to neuroleptic drugs: Mechanisms, applications, and limitations. Psychoneuroendocrinology, 5, 121–37.Google Scholar
Schildkraut, J. J. (1965) The catecholamine hypothesis—a review of the supporting evidence. American Journal of Psychiatry, 122, 509–22.Google Scholar
Silverstone, T. (1979) Psychopharmacology of manic-depressive illness. In Current Themes in Psychiatry (eds. Gaind, R. N. and Hudson, B. L.). London: Macmillan.Google Scholar
Wald, D., Ebstein, R. P. & Belmaker, R. H. (1978) Haloperidol and lithium blocking of the mood response to intravenous methylphenidate. Psychopharmacology, 57, 83–7.Google Scholar
Wiles, D., Franklin, M., Dencker, S. J., Johansson, R., Lundin, L. & Malru, V. (1980) Plasma fluphenazine and prolactin levels in schizophrenic patients during treatment with low and high doses of fluphenazine enanthate. Psychopharmacology, 71, 131–6.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.